Nutriband Inc.

NASDAQ:NTRB

Biotechnology

Healthcare
$4.82 +22.32%

+$0.85 today

Market cap
$58.59M
Beta
1.97
P/E (TTM)
-1.8
EPS (TTM)
-$0.66
52W Low $2.80High $8.63

Volume 0.03M

Average 0.01M

NTRB Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Nutriband Inc.NASDAQ: NTRB

Research & Development · Q1 FY2026 · quarter ended Apr 2026

Research & development declines year over year

Q1 FY2026 research & development of $247.26K fell 63.8% year over year, behind the -48.6% change in trailing-twelve-month research & development. Sequentially, it rose 31.5% from the prior quarter. Over 3 fiscal years it compounded at +24.4% a year.

Context

  • Research & development amounted to 92.9% of revenue in FY2025, down 52.9 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -63.8% toward the trailing-twelve-month pace of -48.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterApr 2026
$247.26K+31.5% QoQ
Last fiscal yearJan 2026
$1.89M-39.4% YoY
LTMApr 2026
$1.45M-48.6% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-63.8%——
1 year-39.4%——
3-year CAGR+24.4%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
1.89M USD
Year-over-year change
-39.4%
4-year CAGR
+46.4%

Research & Development vs competitors

How NTRB compares with its peers on the latest reported figures

  • NTRB's LTM Apr 2026 research & development of $1.45M is the lowest of the 9 companies compared; the peer median is $35.53M.
  • Its year-over-year change of -48.6% is the 6th highest of 8, against a peer median of -5.4%.
  • Research & development amounts to 80.7% of revenue for NTRB, versus a peer median of 1163.2%.
NTRB Competitors Peer median
Research & Development for NTRB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TCRXTScan Therapeutics, Inc.LTM Mar 2026$106.27M -5.4%+24.0%1163.2%
ACETAdicet Bio, Inc.LTM Mar 2026$93.8M -4.5%+11.6%—
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$59.66M -11.8%+35.8%—
XBITXBiotech Inc.LTM Mar 2026$40.98M +3.6%+14.5%—
ADAGAdagene Inc.LTM Jun 2024$30.07M —-35.3%3686.7%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$23.02M -48.6%-81.3%—
GANXGain Therapeutics, Inc.LTM Mar 2026$10.72M +1.7%+6.8%—
FBIOFortress Biotech, Inc.LTM Mar 2026$8.51M -76.4%-55.5%12.9%
NTRBNutriband Inc.LTM Apr 2026$1.45M -48.6%+24.4%80.7%
Peer median (excluding NTRB) $35.53M-5.4%+9.2%1163.2%

Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Jan 2024
FY2024
Jan 2025
FY2025
Jan 2026
Revenue1.42M2.08M2.09M2.14M2.04M
Cost of Revenue917.84K1.33M1.22M1.44M1.47M
Gross Profit504.31K750.41K862.11K699.3K566.31K
Gross Margin35.5%36.1%41.3%32.7%27.8%
Research & Development411.38K982.23K1.96M3.12M1.89M
Selling, General & Admin4.02M3.92M3.77M4.27M6.99M
Operating Expenses4.43M4.9M5.73M7.39M8.88M
Depreciation & Amortization318.26K368.96K287.72K285.05K193.8K
EBITDA(5.74M)(4.11M)(5.12M)(10.18M)(8.01M)
EBITDA Margin-403.6%-197.5%-245.6%-475.5%-393.5%
Operating Income(3.93M)(4.15M)(4.87M)(6.69M)(8.32M)
Operating Margin-276.3%-199.5%-233.6%-312.6%-408.4%
Interest Income0016.85K191.67K0
Interest Expense118.42K8.29K75.82K21.41K22.54K
Other Income / Expenses(2.25M)(335.62K)(613.39K)(3.79M)88.33K
Income Before Tax(6.18M)(4.48M)(5.49M)(10.48M)(8.23M)
Pre-Tax Margin-434.3%-215.6%-263.0%-489.9%-404.1%
Income Tax Expense00000
Net Income(8.42M)(4.81M)(5.49M)(10.48M)(8.23M)
Net Margin-592.2%-231.3%-263.0%-489.9%-404.1%
EPS (Basic)(1.06)(0.57)(0.69)(0.99)(2.58)
EPS (Diluted)(1.06)(0.57)(0.69)(0.99)(2.58)
Weighted Avg Shares7.93M8.46M7.95M10.61M11.64M
Weighted Avg Shares (Diluted)7.93M8.46M7.95M10.61M11.64M

Nutriband Inc.

NASDAQ:NTRB

Intrinsic Alpha fair value

Locked

Current Price

$4.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.